Zhang Mei-Mei, Gong Zhi-Cheng, Zhao Qi, Xu Ding-Qiao, Fu Rui-Jia, Tang Yu-Ping, Chen Yan-Yan
Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi Key Laboratory of New Drugs and Chinese Medicine Foundation Research, State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), Shaanxi Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an, 712046, Shaanxi Province, China.
Wuxi Institute of Chinese and Western Integrative Medicine, and Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, 214062, Jiangsu Province, China.
J Ethnopharmacol. 2023 Jul 15;311:116431. doi: 10.1016/j.jep.2023.116431. Epub 2023 Mar 30.
Sennoside A is a natural anthraquinone component mainly derived from rhubarb and has been routinely used as a clinical stimulant laxative. However, long-term application of sennoside A may lead to drug resistance and even adverse reactions, thus limiting its clinical use. Therefore, to reveal the time-dependent laxative effect and potential mechanism of sennoside A is of critical importance.
This study was conducted to investigate the time-dependent laxative effect of sennoside A and unveil its underlying mechanism from the perspective of gut microbiota and aquaporins (AQPs).
Based on a mouse constipation model, 2.6 mg/kg sennoside A was administered orally for 1, 3, 7, 14 and 21 days, respectively. The laxative effect was assessed by the fecal index and fecal water content, the histopathology of the small intestine and colon was evaluated by hematoxylin-eosin staining. Gut microbiota changes was observed by 16S rDNA sequencing, and colonic AQPs expression was analyzed by quantitative real-time polymerase chain reaction and western blotting. Partial least-squares regression (PLSR) was used to screen out the effective indicators contributing to the laxative effect of sennoside A. The effective indicators were then fitted to time by a drug-time curve model to analyze the trend of efficacy of sennoside A, and the optimal time of administration was derived by comprehensive analysis with a three-dimensional (3D) time-effect image.
Sennoside A had a significant laxative effect at 7 days of administration with no pathological changes in the small intestine or colon; however, at 14 or 21 days of administration, the laxative effect diminished and slight damage to the colon was observed. Sennoside A affects the structure and function of gut microbes. The alpha diversity showed that the abundance and diversity of gut microorganisms reached the highest value after 7 days of administration. Partial least squares discriminant analysis showed that the composition of the flora was close to normal when administered for less than 7 days, but was closest to the composition of constipation over 7 days. The expression of aquaporin 3 (AQP3) and aquaporin 7 (AQP7) decreased gradually after the administration of sennoside A, with the lowest expression at 7 days, and then increased gradually afterwards, while the expression of aquaporin 1 (AQP1) was the opposite. The PLSR results showed that AQP1, AQP3, Lactobacillus, Romboutsia, Akkermansia and UCG_005 contributed more to the laxative effect of the fecal index, and after fitting with the drug-time curve model, each index showed a trend of increasing and then decreasing. The comprehensive evaluation of the 3D time-effect image concluded that the laxative effect of sennoside A reached its best after 7 days of administration.
Sennoside A should be used in regular dosages for less than one week, as it provides significant relief of constipation and exhibits no colonic damage within 7 days of administration. In addition, Sennoside A exerts its laxative effect by regulating gut microbiota of Lactobacillus Romboutsia, Akkermansia and UCG_005 and water channels of AQP1 and AQP3.
番泻苷A是一种主要从大黄中提取的天然蒽醌成分,一直被常规用作临床刺激性泻药。然而,长期应用番泻苷A可能导致耐药性甚至不良反应,从而限制了其临床应用。因此,揭示番泻苷A的时间依赖性通便作用及其潜在机制至关重要。
本研究旨在探讨番泻苷A的时间依赖性通便作用,并从肠道微生物群和水通道蛋白(AQP)的角度揭示其潜在机制。
基于小鼠便秘模型,分别以2.6mg/kg的剂量口服给予番泻苷A 1、3、7、14和21天。通过粪便指数和粪便含水量评估通便效果,用苏木精-伊红染色评估小肠和结肠的组织病理学。通过16S rDNA测序观察肠道微生物群的变化,用定量实时聚合酶链反应和蛋白质免疫印迹法分析结肠AQP的表达。采用偏最小二乘回归(PLSR)筛选出对番泻苷A通便作用有贡献的有效指标。然后通过药物-时间曲线模型将有效指标与时间拟合,分析番泻苷A的疗效趋势,并通过三维(3D)时间-效应图像进行综合分析得出最佳给药时间。
番泻苷A在给药7天时具有显著的通便作用,小肠和结肠无病理变化;然而,在给药14天或21天时,通便作用减弱,且观察到结肠有轻微损伤。番泻苷A影响肠道微生物的结构和功能。α多样性分析表明,给药7天后肠道微生物的丰度和多样性达到最高值。偏最小二乘判别分析表明,给药少于7天时菌群组成接近正常,但超过7天时最接近便秘时的组成。番泻苷A给药后水通道蛋白3(AQP3)和水通道蛋白7(AQP7)的表达逐渐降低,在7天时表达最低,之后逐渐升高,而水通道蛋白1(AQP1)的表达则相反。PLSR结果表明,AQP1、AQP3、乳酸杆菌属、罗姆布茨菌属、阿克曼氏菌属和UCG_005对粪便指数的通便作用贡献更大,经药物-时间曲线模型拟合后,各指标均呈现先升高后降低的趋势。3D时间-效应图像的综合评价得出,番泻苷A在给药7天后通便效果最佳。
番泻苷A应以常规剂量使用少于一周,因为它能显著缓解便秘,且在给药7天内无结肠损伤。此外,番泻苷A通过调节乳酸杆菌属、罗姆布茨菌属、阿克曼氏菌属和UCG_005的肠道微生物群以及AQP1和AQP3的水通道发挥其通便作用。